Pharma giants announce diabetes drug partnership

04/29/2013 | PharmaLive.com

Merck and Pfizer announced plans to combine Merck's DPP-4 inhibitor Januvia with Pfizer's SGLT-2 inhibitor ertugliflozin to treat type 2 diabetes. Merck paid Pfizer $60 million and will split costs and revenue 60-40 with Pfizer. "This is like the Yankees and Red Sox combining their scouting departments," former Pfizer research chief John LaMattina wrote on Twitter, but Diabetic Investor publisher David Kliff said the resulting drug will be just "another tool in the toolbox."

View Full Article in:

PharmaLive.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN